$CRIS
Curis Inc Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000119312515176676 Filed on May 07, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q1
Revenue	$2.083M	$1.658M	$1.285M
YoY Change	-56.62%	29.06%	47.42%
Cost Of Revenue	$100.0K	$24.43M	$70.00K
YoY Change	11.11%	34800.0%	133.33%
Gross Profit	$1.980M	-$22.77M	$1.220M
YoY Change	-57.96%	-1966.39%	45.24%
Gross Profit Margin	95.06%	-1373.34%	94.97%
Selling, General & Admin	$3.410M	$3.530M	$2.830M
YoY Change	16.38%	24.73%	10.12%
% of Gross Profit	172.22%		231.97%
Research & Development	$2.000M	$4.719M	$3.146M
YoY Change	-39.92%	50.0%	19.69%
% of Gross Profit	101.01%		257.86%
Depreciation & Amortization	$40.00K	$40.00K	$40.00K
YoY Change	33.33%	0.0%	33.33%
% of Gross Profit	2.02%		3.28%
Operating Expenses	$2.000M	$4.719M	$3.146M
YoY Change	-39.92%	50.0%	19.69%
Operating Profit	-$7.369M	-$31.02M	-$4.753M
YoY Change	377.02%	552.64%	9.09%
Interest Expense	$843.0K	$866.9K	$951.0K
YoY Change	-11.24%	-8.84%	0.33%
% of Operating Profit
Other Income/Expense, Net	-$759.0K	-$826.7K	-$810.6K
YoY Change	116.24%	1.98%	34.0%
Pretax Income	-$8.130M	-$31.85M	-$5.560M
YoY Change	327.89%	472.84%	12.1%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$8.129M	-$31.85M	-$5.564M
YoY Change	328.79%	472.4%	12.12%
Net Earnings / Revenue	-390.25%	-1920.87%	-433.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$316.7K	-$1.475M	-$323.6K
COMMON SHARES
Basic Shares Outstanding	128.3M shares	103.2M shares	85.95M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$99.20M	$100.0M	$57.80M
YoY Change	77.78%	73.01%	14.46%
Cash & Equivalents	$31.49M	$23.47M	$7.908M
Short-Term Investments	$67.70M	$76.50M	$49.90M
Other Short-Term Assets	$800.0K	$800.0K	$500.0K
YoY Change	100.0%	60.0%	25.0%
Inventory
Prepaid Expenses
Receivables	$2.093M	$1.769M	$1.369M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$102.1M	$102.6M	$59.65M
YoY Change	67.33%	71.93%	15.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$323.1K	$364.0K	$408.6K
YoY Change	-26.46%	-10.92%	2.16%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$7.200M	$6.100M
YoY Change	-100.0%	18.03%	64.86%
Other Assets	$61.72K	$60.87K	$91.17K
YoY Change	-21.19%	-33.23%	-69.61%
Total Long-Term Assets	$9.519M	$16.76M	$15.72M
YoY Change	-26.26%	6.62%	17.28%
TOTAL ASSETS
Total Short-Term Assets	$102.1M	$102.6M	$59.65M
Total Long-Term Assets	$9.519M	$16.76M	$15.72M
Total Assets	$111.6M	$119.3M	$75.36M
YoY Change	50.98%	58.31%	15.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.385M	$2.782M	$2.545M
YoY Change	-16.28%	9.33%	15.68%
Accrued Expenses	$1.818M	$1.365M	$1.246M
YoY Change	20.43%	9.5%	3.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.846M	$5.584M	$3.392M
YoY Change	-11.86%	64.61%	1030.81%
Total Short-Term Liabilities	$9.050M	$9.731M	$7.809M
YoY Change	-8.82%	24.62%	116.91%
LONG-TERM LIABILITIES
Long-Term Debt	$21.79M	$21.80M	$26.82M
YoY Change	-10.59%	-18.74%	-10.59%
Other Long-Term Liabilities	$158.5K	$168.3K	$194.7K
YoY Change	-17.03%	-13.56%	-83.77%
Total Long-Term Liabilities	$21.95M	$21.96M	$27.02M
YoY Change	-10.64%	-18.71%	-13.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.050M	$9.731M	$7.809M
Total Long-Term Liabilities	$21.95M	$21.96M	$27.02M
Total Liabilities	$31.00M	$31.69M	$34.83M
YoY Change	-10.12%	-8.99%	0.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$819.5M	-$811.4M	-$766.4M
YoY Change	6.67%	5.87%
Common Stock	$901.6M	$900.5M	$871.7K
YoY Change	103265.65%	103208.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$80.58M	$87.62M	$40.54M
YoY Change
Total Liabilities & Shareholders Equity	$111.6M	$119.3M	$75.36M
YoY Change	50.98%	58.31%	15.77%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$8.129M	-$31.85M	-$5.564M
YoY Change	328.79%	472.4%	12.12%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$40.00K
YoY Change	33.33%	0.0%	33.33%
Cash From Operating Activities	-$6.790M	-$7.760M	-$5.310M
YoY Change	43.55%	46.14%	22.63%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$14.96K
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$15.73M	-$40.57M	$3.440M
YoY Change	126.01%	-1279.36%	164.62%
Cash From Investing Activities	$15.73M	-$40.58M	$3.440M
YoY Change	127.97%	-1279.65%	173.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$64.60M	$180.4K
YoY Change		35703.16%	-39.39%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-920.0K	64.06M	180.0K
YoY Change	-1250.0%	35488.89%	350.0%
NET CHANGE
Cash From Operating Activities	-6.790M	-7.760M	-5.310M
Cash From Investing Activities	15.73M	-40.58M	3.440M
Cash From Financing Activities	-920.0K	64.06M	180.0K
Net Change In Cash	8.020M	15.72M	-1.690M
YoY Change	256.44%	-1030.18%	-44.22%
FREE CASH FLOW
Cash From Operating Activities	-$6.790M	-$7.760M	-$5.310M
Capital Expenditures	$0.00	$14.96K
Free Cash Flow	-$6.790M	-$7.775M	-$5.310M
YoY Change	45.4%	46.42%	21.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128339695	shares
CY2015Q1	cris	Accrued Public Offering Costs Current AccruedPublicOfferingCostsCurrent	240590
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7907869
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	129560541	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128337695	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9731127
CY2015Q1	us-gaap	Interest Payable Current InterestPayableCurrent	295165
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	1295605
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2402
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2782399
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-811403518
CY2015Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5584136
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	899250204
CY2015Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	722090
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1364592
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	87615860
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	168319
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	188862
CY2015Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21795103
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119310409
CY2015Q1	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	158475
CY2015Q1	us-gaap	Liabilities Liabilities	31694549
CY2015Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14305
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23467545
CY2015Q1	us-gaap	Goodwill Goodwill	8982000
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	364005
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4881000
CY2015Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	83685781
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	828252
CY2015Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2015Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15036
CY2015Q1	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2015Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	76488863
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3832000
CY2015Q1	us-gaap	Long Term Investments LongTermInvestments	7196918
CY2015Q1	us-gaap	Assets Assets	119310409
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5611000
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1769344
CY2015Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	83686512
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60872
CY2015Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2015Q1	us-gaap	Assets Current AssetsCurrent	102554004
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1612322	shares
CY2010Q1	cris	Registered Direct Offering Number Of Warrant Per Unit RegisteredDirectOfferingNumberOfWarrantPerUnit	1
CY2010Q1	cris	Registered Direct Offering Number Of Common Stock Per Unit RegisteredDirectOfferingNumberOfCommonStockPerUnit	1
CY2010Q1	cris	Registered Direct Offering Units RegisteredDirectOfferingUnits	6449288	shares
CY2010Q1	cris	Direct Offering Purchase Price DirectOfferingPurchasePrice	2.52
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9591487
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87253657	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86030811	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10066867
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	286075
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	872537
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10997
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2349183
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-779555295
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5709985
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	810001410
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1386226
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2007699
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	29783626
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	174018
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	212548
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	22589058
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62613569
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	122850
CY2014Q4	us-gaap	Liabilities Liabilities	32829943
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4883
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7747411
CY2014Q4	us-gaap	Goodwill Goodwill	8982000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	407738
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	42791550
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	489844
CY2014Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15880
CY2014Q4	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42002782
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	788768
CY2014Q4	us-gaap	Assets Assets	62613569
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1960995
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	42802547
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	67544
CY2014Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2014Q4	us-gaap	Assets Current AssetsCurrent	52214909
CY2014Q4	cris	Stock Issued During Period Due To Exercise Of Warrants StockIssuedDuringPeriodDueToExerciseOfWarrants	238805	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.20
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.65	pure
CY2010Q1	cris	Proceeds From Registered Direct Offering Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts	14942000
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	25090908	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64619407
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.09
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	20000000
CY2015Q1	cris	Percentage Of Royalty To Be Received PercentageOfRoyaltyToBeReceived	0.10	pure
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12706573	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.71	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.022	pure
CY2015Q1	cris	Non Royalty Consideration Percentage NonRoyaltyConsiderationPercentage	0.15	pure
CY2015Q1	cris	Percentage Of Royalty On Net Sales PercentageOfRoyaltyOnNetSales	0.03	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1040000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.97
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5305886
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85917592	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.019	pure
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	910000
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	55672
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	46102
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6420
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4753343
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5559702
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1288248
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-810593
CY2014Q1	us-gaap	Revenues Revenues	1284633
CY2014Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13388600
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-5563936
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	48760
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-108268
CY2014Q1	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	353619
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48011
CY2014Q1	us-gaap	Interest Expense InterestExpense	950976
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	26213
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1683618
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-91623
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37019
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	180431
CY2014Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	180431
CY2014Q1	us-gaap	Royalty Expense RoyaltyExpense	65148
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3441837
CY2014Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3145930
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	6037976
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	16816560
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2826898
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-159130
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	743444
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	88000
CY2014Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	258050
CY2014Q1	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	3615
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.68	pure
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
CY2015Q1	dei	Trading Symbol TradingSymbol	CRIS
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q1	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>1. <u>Nature of Business</u></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s clinical drug candidates include CUDC-907, a dual histone deacetylase, or HDAC and phosphoinositide-3 kinase, or PI3K, inhibitor, CUDC-427, a small molecule antagonist of the inhibitor of apoptosis, or IAP, proteins, and CUDC-305, a Heat Shock Protein 90, or HSP90, inhibitor. Erivedge<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">®</sup>, the first and only approved medicine for the treatment of advanced basal cell carcinoma, or BCC, is being commercialized by F. Hoffmann-La Roche Ltd., or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene (see Note 4(b)). The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The first two programs under the collaboration are focused on the development of orally-available small molecule antagonists of programmed death ligand-1 (PD-L1) in the immuno-oncology field and orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is subject to risks common to companies in the biotechnology industry as well as risk that are specific to the Company’s business, including, but not limited to: the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement; the Company’s ability to advance and expand its research and development programs; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s future operating results will largely depend on the magnitude of payments that it receives and makes under its current and potential future corporate collaborations and the progress of drug candidates currently in its development pipeline. The results of the Company’s operations will vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Roche and Genentech’s ongoing clinical trials; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; and the Company’s ability to successfully enter into one or more material outlicensing or collaboration agreements for its proprietary drug candidates.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company anticipates that existing cash, cash equivalents and investments at March 31, 2015 should enable it to maintain current and planned operations into 2017. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech and the Leukemia & Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</p> </div>
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7759196
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.25
CY2015Q1	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	The Company has agreed to make each of the following one-time payments to Debiopharm (i) $3,000,000 within 30 days after the first dosing of the first patient in the first Phase 3 clinical trial of Debio 0932; and (ii) $10,000,000 within 30 days after receipt of the first marketing approval for Debio 0932 in the United States of America or any specified major European market (whichever occurs first).
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	0	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	107934493	shares
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.016	pure
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.94
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70	pure
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.017	pure
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12650494	shares
CY2015Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	896000
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	120158
CY2015Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	306760
CY2015Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	1768491
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	336364
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-31021549
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31839628
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1671070
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-826674
CY2015Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2240
CY2015Q1	us-gaap	Revenues Revenues	1658332
CY2015Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	57561876
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14957
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-31848223
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	40271
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-191651
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120828
CY2015Q1	us-gaap	Interest Expense InterestExpense	866945
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18703
CY2015Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	929339
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15720134
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41493
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	64059286
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64859997
CY2015Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	128628
CY2015Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	24347815
CY2015Q1	us-gaap	Royalty Expense RoyaltyExpense	84092
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-40579956
CY2015Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4718972
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	32679881
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	16983000
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3529002
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-441223
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	951104
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	60000
CY2015Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	24089027
CY2015Q1	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-929339
CY2015Q1	cris	Obligation Limit ObligationLimit	2.50	pure
CY2015Q1	cris	Royalties Terms Of Collaboration Agreement RoyaltiesTermsOfCollaborationAgreement	The term of the collaboration agreement begins upon signing and, unless earlier terminated, will expire upon either (i) 90 days after the completion by Aurigene of its obligations under all research plans if the Company has not exercised the option with respect to at least one program by such time; or (ii) expiration of the last-to-expire royalty term for any and all products.
CY2015Q1	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	12738
CY2015Q1	cris	Issuance Of Common Stock To Licensees IssuanceOfCommonStockToLicensees	23968183
CY2015Q1	cris	Class Of Warrant Or Right Expiration Date ClassOfWarrantOrRightExpirationDate	2015-01-27
CY2015Q1	cris	Class Of Warrant Expired ClassOfWarrantExpired	1373517	shares
CY2015Q1	cris	Contingent Obligations ContingentObligations	4125000
CY2015Q1	cris	Compensation Expenses Related To Agreement CompensationExpensesRelatedToAgreement	750000
CY2015Q1	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	Plans
CY2015Q1	cris	Equity Issuance Costs Unpaid And Accrued EquityIssuanceCostsUnpaidAndAccrued	240590

Files In Submission

Name	View Source	Status
0001193125-15-176676-index-headers.html	Edgar Link	pending
0001193125-15-176676-index.html	Edgar Link	pending
0001193125-15-176676.txt	Edgar Link	pending
0001193125-15-176676-xbrl.zip	Edgar Link	pending
cris-20150331.xml	Edgar Link	completed
cris-20150331.xsd	Edgar Link	pending
cris-20150331_cal.xml	Edgar Link	unprocessable
cris-20150331_def.xml	Edgar Link	unprocessable
cris-20150331_lab.xml	Edgar Link	unprocessable
cris-20150331_pre.xml	Edgar Link	unprocessable
d909978d10q.htm	Edgar Link	pending
d909978dex311.htm	Edgar Link	pending
d909978dex312.htm	Edgar Link	pending
d909978dex321.htm	Edgar Link	pending
d909978dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
Curis Inc Stock $cris

2015 Q2 Form 10-Q Financial Statement

#000119312515176676 Filed on May 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS Curis Inc Stock $cris

2015 Q2 Form 10-Q Financial Statement

#000119312515176676 Filed on May 07, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
Curis Inc Stock $cris